{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:09:29Z","timestamp":1785820169092,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Mol Morphol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00795-020-00261-7","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T09:07:50Z","timestamp":1595408870000},"page":"52-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["PD-L1 expression in tongue squamous cell carcinoma"],"prefix":"10.1007","volume":"54","author":[{"given":"Naoki","family":"Akisada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soshi","family":"Takao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Gion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Marunaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munechika","family":"Tsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Toji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Nishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yorihisa","family":"Orita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"261_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359\u2013E386","journal-title":"Int J Cancer"},{"key":"261_CR2","first-page":"163","volume":"14","author":"DG Pfister","year":"2000","unstructured":"Pfister DG, Ang K, Brockstein B, Colevas AD, Ellenhorn J, Goepfert H, Hicks WL, Hong WK, Kies MS, Lydiatt W, McCaffrey T, Mittal BB, Ridge JA, Schuller DE, Shah JP, Spencer S, Trotti A, Urba S, Weymuller EA, Wheeler RH, Wolf GT (2000) NCCN practice guidelines for head and neck cancers. Oncology 14:163\u2013194","journal-title":"Oncology"},{"key":"261_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12032-018-1096-5","volume":"35","author":"A Guidi","year":"2018","unstructured":"Guidi A, Codec\u00e0 C, Ferrari D (2018) Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. Med Oncol 35:37","journal-title":"Med Oncol"},{"key":"261_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116\u20131127","journal-title":"N Engl J Med"},{"key":"261_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.oraloncology.2017.07.023","volume":"73","author":"N Kiyota","year":"2017","unstructured":"Kiyota N, Hasegawa Y, Takahashi S, Yokota T, Yen C-J, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Namba Y, Monga M, Lynch M, Tahara M (2017) A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncol 73:138\u2013146","journal-title":"Oral Oncol"},{"key":"261_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12105-017-0857-3","volume":"12","author":"T Scognamiglio","year":"2018","unstructured":"Scognamiglio T, Chen Y-T (2018) Beyond the percentages of PD-L1-positive tumor cells: induced versus constitutive PD-L1 expression in primary and metastatic head and neck squamous cell carcinoma. Head Neck Pathol 12:221\u2013229","journal-title":"Head Neck Pathol"},{"key":"261_CR7","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856\u20131867","journal-title":"N Engl J Med"},{"key":"261_CR8","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan B (2010) International Union Against Cancer (UICC). Lip and oral cavity. In: Sobin LH, Gospo- darowicz MK, Wittekind C (eds) TNM classification of malignant tumours. 7th ed. New York: Wiley; 2010. p. 25\u201329","DOI":"10.1002\/9780471420194.tnmc03.pub2"},{"key":"261_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM (2017) PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol 12:208\u2013222","journal-title":"J Thorac Oncol"},{"key":"261_CR10","first-page":"2259","volume":"15","author":"SC Chen","year":"2018","unstructured":"Chen SC, Chang PMH, Wang HJ, Tai SK, Chu PY, Yang MH (2018) PD-L1 expression is associated with p16INK4Aexpression in non-oropharyngeal head and neck squamous cell carcinoma. Oncol Lett 15:2259\u20132265","journal-title":"Oncol Lett"},{"key":"261_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/his.13646","volume":"73","author":"S Schneider","year":"2018","unstructured":"Schneider S, Kadletz L, Wiebringhaus R, Kenner L, Selzer E, F\u00fcreder T, Rajky O, Berghoff AS, Preusser M, Heiduschka G (2018) PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. Histopathology 73:573\u2013584","journal-title":"Histopathology"},{"key":"261_CR12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.pathol.2016.07.003","volume":"48","author":"L Satgunaseelan","year":"2016","unstructured":"Satgunaseelan L, Gupta R, Madore J, Chia N, Lum T, Palme CE, Boyer M, Scolyer RA, Clark JR (2016) Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology 48:574\u2013580","journal-title":"Pathology"},{"key":"261_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ijom.2018.01.004","volume":"47","author":"Y Maruse","year":"2018","unstructured":"Maruse Y, Kawano S, Jinno T, Matsubara R, Goto Y, Kaneko N, Sakamoto T, Hashiguchi Y, Moriyama M, Toyoshima T, Kitamura R, Tanaka H, Oobu K, Kiyoshima T, Nakamura S (2018) Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 47:836\u2013845","journal-title":"Int J Oral Maxillofac Surg"},{"key":"261_CR14","doi-asserted-by":"publisher","first-page":"12024","DOI":"10.18632\/oncotarget.7593","volume":"7","author":"M Straub","year":"2016","unstructured":"Straub M, Drecoll E, Pfarr N, Weichert W, Langer R, Hapfelmeier A, G\u00f6tz C, Wolff KD, Kolk A, Specht K (2016) CD274\/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget Impact J 7:12024\u201312034","journal-title":"Oncotarget Impact J"},{"key":"261_CR15","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","volume":"35","author":"J Bauml","year":"2017","unstructured":"Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Schu X, Cheng JD, Haddad R (2017) Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol 35:1542\u20131549","journal-title":"J Clin Oncol"},{"key":"261_CR16","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018\u20132028","journal-title":"N Engl J Med"},{"key":"261_CR17","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, Molina J, Kim J, Arvis CD, Ahn M, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, ShentuY IME, Dolled Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550","journal-title":"Lancet"},{"key":"261_CR18","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833","journal-title":"N Engl J Med"},{"key":"261_CR19","first-page":"5713","volume":"37","author":"N Haratake","year":"2017","unstructured":"Haratake N, Toyokawa G, Tagawa T, Kozuma Y, Matsubara T, Takamori S, Akamine T, Yamada Y, Oda Y, Maehara Y (2017) Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab. Anticancer Res 37:5713\u20135717","journal-title":"Anticancer Res"},{"key":"261_CR20","doi-asserted-by":"crossref","unstructured":"Lin Y, Sung W, Hsieh M, Tsai S, Lai H, Yang S, Chen K, Chen M, Lee H, Yeh K, Chen C (2015) High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. Suzuki H, editor. PLoS ONE 10:e0142656","DOI":"10.1371\/journal.pone.0142656"},{"key":"261_CR21","first-page":"568","volume":"47","author":"GJ Hanna","year":"2018","unstructured":"Hanna GJ, Woo SB, Li YY, Barletta JA, Hammerman PS, Lorch JH (2018) Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. Oral Maxillofacial Surg 47:568\u2013577","journal-title":"Oral Maxillofacial Surg"}],"updated-by":[{"DOI":"10.1007\/s00795-020-00270-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000}}],"container-title":["Medical Molecular Morphology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00795-020-00261-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00795-020-00261-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00795-020-00261-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T10:12:16Z","timestamp":1627639936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00795-020-00261-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["261"],"URL":"https:\/\/doi.org\/10.1007\/s00795-020-00261-7","relation":{},"ISSN":["1860-1480","1860-1499"],"issn-type":[{"value":"1860-1480","type":"print"},{"value":"1860-1499","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"16 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00795-020-00270-6","URL":"https:\/\/doi.org\/10.1007\/s00795-020-00270-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors declare that: (i) no support, financial or otherwise, has been received from any organization that may have an interest in the submitted work; and (ii) there are no other relationships or activities that could appear to have influenced the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}}]}}